Insurance-backed MDMA-Assisted Therapy for PTSD
Tracks
Ballroom 1 - Virtual via OnAIR
| Wednesday, June 24, 2026 |
| 11:00 AM - 11:30 AM |
Overview
Dr Michael Winlo, Emyria Limtied
Details
Durable Outcomes: MDMA-AT delivered in real-world clinical settings can produce sustained symptom reduction and functional recovery in patients with complex trauma histories.
The Patient Journey Matters: Careful attention to patient selection, preparation, and follow-up is critical to maximise safety, predict response, and maintain long-term benefit.
Real-World Evidence is Essential: Large-scale, payer-supported programs provide unique data that complement traditional trials and help set new standards for the safe and scalable delivery of psychedelic-assisted therapies.
Presenter
Dr Michael Winlo
Chief Scientific Officer
Emyria Limtied
Insurance-backed MDMA-Assisted Therapy for PTSD
Biography
Dr. Michael Winlo is Chief Scientific Officer at Emyria Limited (ASX:EMD), a mental health services company pioneering innovative treatments for PTSD and depression. A medical doctor with an MBA from Stanford, Michael founded Emyria’s MDMA-Assisted Therapy (MDMA-AT) program for PTSD, the first and only program in Australia to receive funding support from Medibank, reducing barriers to care. Under his leadership, Emyria has built a national network of specialist treatment centres, uniquely positioned to gather real-world evidence and patient outcomes at scale. Michael’s work focuses on translating breakthrough science into safe, accessible, and effective therapies.
